US 12,109,277 B2
Methods and kits for preparing radionuclide complexes
Philip Blower, London (GB); and Gregory Mullen, Reading (GB)
Assigned to Theragnostics Limited, London (GB)
Filed by Theragnostics Limited, London (GB)
Filed on Nov. 1, 2023, as Appl. No. 18/499,758.
Application 18/499,758 is a continuation of application No. 17/857,990, filed on Jul. 5, 2022, granted, now 11,826,436.
Application 17/857,990 is a continuation of application No. 17/154,926, filed on Jan. 21, 2021.
Application 17/154,926 is a continuation of application No. 15/554,573, abandoned, previously published as PCT/GB2016/050637, filed on Mar. 9, 2016.
Claims priority of application No. 1504064 (GB), filed on Mar. 10, 2015.
Prior Publication US 2024/0165277 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/04 (2006.01); A61B 5/00 (2006.01); A61K 51/08 (2006.01); A61P 35/00 (2006.01); C01G 15/00 (2006.01); C07B 59/00 (2006.01); C07C 251/24 (2006.01); C07F 5/00 (2006.01)
CPC A61K 51/0478 (2013.01) [A61B 5/0035 (2013.01); A61K 51/082 (2013.01); A61K 51/088 (2013.01); A61P 35/00 (2018.01); C01G 15/00 (2013.01); C07B 59/00 (2013.01); C07C 251/24 (2013.01); C07F 5/00 (2013.01)] 7 Claims
 
1. A method for obtaining a molecular image of a patient in need thereof, the method comprising:
(a) preparing radiolabeled DKFZ-PSMA-11, wherein said preparing comprises adding a 0.1 M HCL gallium radioisotope eluate to a chelator composition at a temperature of from 10° C. to 30° C., thereby producing a preparation of radiolabeled DKFZ-PSMA-11, wherein the chelator composition comprises:
(i) an amount of a pharmaceutically acceptable buffer selected from a phosphate buffer or acetate buffer, wherein the amount of the buffer is sufficient to increase the pH of the preparation to a level in the range of from 3 to 8; and
(ii) DKFZ-PSMA-11,
wherein the chelator composition is lyophilized or freeze-dried and does not include an agent that inhibits a metal other than gallium, and
wherein the 0.1 M HCL gallium radioisotope eluate is directly from a gallium-68 radionuclide generator without an additional purification step or concentration step;
(b) administering the preparation of the radiolabeled DKFZ-PSMA-11 to the patient; and
(c) obtaining the molecular image of the patient using a molecular imaging technique.